Leadership
Learn more about our CEO and leadership’s backgrounds to see how they drive for great impact across the medical field.
Clare Kahn is a member of the Board of Directors at Stoke Therapeutics.
Dr. Kahn currently leads Clare Kahn Pharma Consulting LLC. She recently served as R&D Strategy Officer and Chief Regulatory and Preclinical Development Officer at X-VAX Technology, Inc. A member of the Board of Directors at Solid Biosciences since 2021, she also participates as an advisor for Pfizer’s vaccine portfolio and is a subject matter expert reviewer for the Gates Foundation. She previously served on the advisory boards to Xylocor (2016-2018) and KBP (2016-2023).
Dr. Kahn joined Pfizer in 2010 as Vice President and Head of Worldwide Regulatory for the specialty care portfolio before expanding her role to lead Pfizer’s Global Innovative Pharma business, comprising the specialty care and primary care portfolios. Previously, she led GSK’s regulatory strategy for several portfolios including vaccines, cardiovascular/metabolic and oncology.
Earlier in her career, Dr. Kahn was a faculty member at the University of Pennsylvania where she served as Assistant Professor in the Departments of Pharmacology and Pathology & Laboratory Medicine and as a member of the Executive Committee of the Graduate Group in Pharmacological Sciences.
Dr. Kahn holds a Ph.D. in Biochemical Pharmacology from the Department of Clinical Pharmacology at The Royal Postgraduate Medical School, London.